Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wedbush analyst Yun Zhong initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Targ...
Chardan Capital analyst Daniil Gataulin initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Pri...
Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inh...
Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal di...
Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal di...
-SEC Filing
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) ...
Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH...
